About one third of the patients with epilepsy are not satisfactorily controlled in spite of correct anticonvulsive treatment. Although the ketogenic diet has been used for refractory epilepsy since the 1920s, over the past ten years it has been used much more, OBJECTIVE. To review the effectiveness, tolerance and adverse effects in 12 paediatric patients who have been on this diet for over three months. Patients and methods. We assessed 15 children, of whom only 12 are included in this review ( 5 boys and 7 girls). After initial joint evaluation by the neuropaediatrician and the Clinical Nutrition Unit the diet was started in hospital with a period of fasting (24-48 hours) until ketosis occurred. The diet was continued over three days before the child was sent home. In our centre we used a diet with modified MCT, in which 30% of the energy was given in the form of MCT and 40% as natural fats. The effectiveness of the diet was found by comparing the number of seizures suffered by the patient before starting the diet with the number at different times later (1, 3, 6, 12, 18 months).
RESULTS The median age when starting on the diet was 3 years and 5 months (range 18 months to 9 years). All had been diagnosed as having the Lennox Gastaut syndrome, six having cryptogenic disease. Six children had severe mental retardation. Six months after starting the diet, half the children had over 50% reduction in seizures whilst a third had no seizures at all or had their frequency of occurrence reduced by over 90%. After one year three families had given up the diet, two because of its inefficacy in controlling the seizures. The diet was well-tolerated in all cases, with levels of ketonuria maintained at 2+. Mild adverse effects were seen in only three patients and transient rise in the plasma cholesterol level in four children.
FULL TEXT(solo disponible en lengua castellana / Only available in Spanish)
Si ya es un usuario registrado en Neurologia, introduzca sus datos de inicio de sesión.
Rellene los campos para registrarse en Neurologia.com y acceder a todos nuestros artículos de forma gratuita
¿Olvidó su contraseña? Introduzca su correo electrónico y le haremos llegar una nueva
Estimado usuario de Revista de Neurología,
Debido a la reciente fusión por absorción de VIGUERA EDITORES, S.L.U., la entidad gestora de las publicaciones de Viguera Editores, entre ellas, Revista de Neurología, por EVIDENZE HEALTH ESPAÑA, S.L.U., una de las sociedades también pertenecientes al Grupo Evidenze, y con la finalidad de que Usted pueda seguir disfrutando de los contenidos y distintos boletines a los que está suscrito en la página web de neurologia.com, es imprescindible que revise la nueva política de privacidad y nos confirme la autorización de la cesión de sus datos.
Lamentamos informarle que en caso de no disponer de su consentimiento, a partir del día 28 de octubre no podrá acceder a la web de neurologia.com
Para dar su consentimiento a seguir recibiendo la revista y los boletines de neurologia.com vía correo electrónico y confirmar la aceptación de la nueva política de privacidad, así como la cesión de sus datos a Evidenze Health España S.L.U., el resto de las entidades del Grupo Evidenze y sus partners y colaboradores comerciales, incluyendo la posibilidad de llevar a cabo transferencias internacionales a colaboradores extranjeros, pulse en el siguiente enlace:
OPEN ACCESS
